Although further functional studies must be conducted to confirm the therapeutic potential of the fatty acid oxidative pathway in aggressive lymphomas, SLC27A1, and the OxPhos pathway, might constitute a promising therapeutic target. This evidence concerns the gene SLC27A1 and lymphoma.